ClinicalTrials.gg
RecruitingNCT06943612COLOSARC-QUpdated Jul 23, 2026

Colorectal Resections in Patients With Retroperitoneal Sarcoma

An observational study in Sarcoma, Soft Tissue and Retroperitoneal Sarcoma, sponsored by Heidelberg University. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Heidelberg University · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.

Planned enrollment
11th of 19
120 · median 130
Started
2025
with 5 others
Observational
19 of 103
7 open now
Primary completion
2026-06
later than 9 of 29 live
Registered
99th of 103
by date
Lead sponsor
5 of 103
Heidelberg University

Among the 103 studies in Sarcoma with a site in Germany, this one is the 11th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2025, is one of 19 observational ones, reaches primary completion later than 9 of the 29 other live ones, and was the 99th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Sarcoma with a site in Germany, or all of them as a file.
02

Study summary

COLOSARC-Q is a multicenter study with the objective of providing an up-to-date assessment of colorectal resections and reconstruction techniques in the context of multivisceral resections for retroperitoneal sarcomas, as well as colorectal surgery-associated complications and their impact on patients' quality of life.

In multivisceral resections involving the colon and rectum, the primary aim is to achieve complete resection and preserve organ function. However, multivisceral resections have a high risk of perioperative morbidity including anastomotic leakage. The proposed project aims to determine the number of primary anastomoses, their insufficiency rates, and the fraction of patients with primary and secondary stomas. In addition, the patients' quality of life after multivisceral sarcoma resection is to be recorded using standardized surveys.

The analysis has the potential to facilitate intraoperative decision-making for colorectal resections in the context of multivisceral resections.

Read the detailed description

The primary goal of retroperitoneal sarcoma surgery is to achieve complete resection. The resection of retroperitoneal sarcomas (RPS) usually involves the removal of parts of the colon. While there is good data on surgical principles and postoperative complications of multivisceral resections in RPS as a whole (1, 2), there is little evidence on the frequency of temporary or permanent stomas and complications associated with intestinal surgery (e.g., number of anastomotic leackages in relation to the number of intestinal anastomoses performed) and their impact on the quality of life of those affected.

The COLOSARC-Q study is a multicenter, non-interventional study with the aim of documenting

  • colorectal resection and reconstruction techniques in connection with multivisceral resections in retroperitoneal sarcomas (RPS),
  • complications associated with intestinal surgery in multivisceral resections, and
  • the resulting effects on the quality of life of sarcoma patients. The project plans to include 120 patients with retroperitoneal sarcomas who have undergone colon resection as part of a multivisceral resection at a DKG-certified sarcoma center or hospital that meets certification-equivalent criteria. For these patients, patient-, tumor-, and treatment-specific parameters (all patients), standardized questionnaires on health-related quality of life (EORTC QLQ - C30 (version 3.0)) and bowel function (EORTC QLQ - CR29) (expected response rate ≥ 50%) and semi-structured interviews with the aim of recording specific problems that may not be covered in the questionnaires (e.g., regarding stoma placement, nutritional status, treatment sequence, or home care; n = 10-15).

COLOSARC-Q has the potential to improve preoperative participatory decision-making and intraoperative strategy in colorectal resections as part of multivisceral resections in order to reduce complication rates and develop surgical strategies tailored to specific patient needs.

03

Conditions studied

  • Sarcoma, Soft Tissue
  • Retroperitoneal Sarcoma

Browse trials for

Keywords

  • Soft tissue sarcoma
  • Retroperitoneal Sarcoma
  • Sarcoma Surgery
  • Stoma
  • Colorectal resection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with primary, retroperitoneal sarcomas who underwent surgery with colorectal resection at DKG-certified sarcoma centers or hospitals in Germany and Switzerland that meet certification-equivalent criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation with evidence of a retroperitoneal sarcoma
  • Tumor resection with colorectal resection
  • Surgery in a DKG-certified sarcoma center or hospital that meets certification-equivalent criteria
  • Age 18 years or older
  • Written consent

Exclusion criteria

Exclusion Criteria:

  • Absence of consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with primary, retroperitoneal sarcomas who underwent surgery with colorectal resection

    Patients with primary retroperitoneal sarcomas who underwent surgery with colorectal resection at DKG-certified sarcoma centers or hospitals in Germany and Switzerland that meet certification-equivalent criteria

06

What researchers measure

Primary outcomes

  1. Evaluation of resection and reconstruction procedures of the colon and rectum in the context of multivisceral resections of retroperitoneal sarcomas

    Description of the surgical procedure, e.g. righ hemicolectomy with primary anastomosis

    Time frame: immediately after the surgery

Secondary outcomes

  1. Postoperative complications associated with resections and reconstructions of the bowel

    Evaluation of postoperative complications associated with resections and reconstructions of the bowel during and after multivisceral resections of retroperitoneal sarcomas (Comprehensive Complication Index (CCI), up to 90 days postoperatively)

    Time frame: up to 90 days after surgery

  2. Assessment of quality of life after colorectal resections in the context of RPS resections

    Assessment of quality of life after using the EORTC QLQ - C30 (Version 3.0) questionnaires)

    Time frame: through study completion, an average of 1 year

  3. Assessment of changes in bowel function after resection of retroperitoneal sarcomas

    Assessment of the bowel function using the EORTC QLQ - CR29 questionnaire

    Time frame: through study completion, an average of 1 year

  4. Identification of problems and needs of RPS patients

    Identification of problems and needs of RPS patients who have undergone resection and reconstruction of the colon, e.g. with regard to education, home care, bowel function, stoma care, rehabilitation measures and therapy intensity and sequence

    Time frame: through study completion, an average of 1 year

  5. Determination of patient-, tumor- and treatment-related factors influencing the above-mentioned primary and secondary study objectives

    Determination of the influence of the following patient-, tumor- and treatment-related factors on the above-mentioned primary and secondary study objectives: * Gender * age * Body mass index (BMI) * Malnutrition (serum albumin preoperatively) * Concomitant diseases (e.g. diabetes mellitus, coronary heart disease) * Previous abdominal surgery * Size, localization (left/right), grading and histological subtype of the RPS * Neoadjuvant therapies (radiotherapy and/or chemotherapy) * Operation time * Intraoperative blood loss * Extent of the surgical procedure

    Time frame: through study completion, an average of 1 year

07

Study locations

16 of 16 sites recruiting
  • Sarcoma Center of University Medical Center Mannheim
    Mannheim, Baden-Wurttemberg 68167, Germany
    Recruiting
  • University Medical Center Goettingen
    Göttingen, Deutschland 37075, Germany
    Recruiting
  • Helios Hospital Berlin-Buch
    Berlin, Germany
    Recruiting
  • University Hospital Koeln
    Cologne, Germany
    Recruiting
  • University Medical Center Dresden
    Dresden, Germany
    Recruiting
  • University Medical Center Erlangen
    Erlangen, Germany
    Recruiting
  • University Medical Center Greifswald
    Greifswald, Germany
    Recruiting
  • University Medical Center Halle
    Halle, Germany
    Recruiting
    • Ulrich Ronellenfitsch, Prof. · Contact+49 345 557 2143
  • University Medical Center Hamburg-Eppendorf
    Hamburg, Germany
    Recruiting
    • Anna Duprée, Dr. · Contact+49 (0) 40 - 7410 - 55692
  • Medical University of Hannover
    Hanover, Germany
    Recruiting
    • Ulrich Zwirner, Dr. · Contact+49 511532 2032
  • Heidelberg University Hospital
    Heidelberg, Germany
    Recruiting
    • Cosima Engerer, Dr. · Contact+49 6221 483713
  • University Hospital Magdeburg
    Magdeburg, Germany
    Recruiting
    • Roland S Croner, Prof. · Contact+49 391 67-15500
  • LMU Hospital
    München, Germany
    Recruiting
    • Markus Albertsmeier, Dr. · Contact+49 (0)89 4400 74798
  • University Medical Center Tübingen
    Tübingen, Germany
    Recruiting
  • University Medical Center Ulm
    Ulm, Germany
    Recruiting
  • Sarcoma Center University of Basel
    Basel, Switzerland
    Recruiting
    • Alexander Willhelm, Dr. · Contact+41 61 777 73 17
08

References and documents

Publications

  • Jakob J, Hentschel L, Richter S, Kreisel I, Hohenberger P, Kasper B, Andreou D, Pink D, Schmitt J, Schuler MK, Eichler M. Transferability of Health-Related Quality of Life Data of Large Observational Studies to Clinical Practice: Comparing Retroperitoneal Sarcoma Patients from the PROSa Study to a TARPS-WG Cohort. Oncol Res Treat. 2022;45(11):660-669. doi: 10.1159/000525288. Epub 2022 Jun 14. PubMed 35700716 ↗
  • MacNeill AJ, Fiore M. Surgical morbidity in retroperitoneal sarcoma resection. J Surg Oncol. 2018 Jan;117(1):56-61. doi: 10.1002/jso.24902. Epub 2018 Jan 3. PubMed 29314041 ↗
  • Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P, Gronchi A. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol. 2012 Sep;19(9):2981-91. doi: 10.1245/s10434-012-2342-2. Epub 2012 Apr 3. PubMed 22476756 ↗
  • Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honore C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Raut CP. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016 May;263(5):1002-9. doi: 10.1097/SLA.0000000000001447. PubMed 26727100 ↗
  • Hettler M, Scharpf KR, Eich A, Albertsmeier M, Dupree A, Hetjens S, Harbrucker M, Menge F, Betzler A, Hohenberger P, Jakob J. Multicentre prospective non-interventional study protocol for evaluating surgical strategies for Colorectal Resections and Postoperative Quality of Life in Retroperitoneal Sarcoma Patients Across German-Speaking Sarcoma Centres (COLOSARC-Q). BMJ Open. 2025 Dec 30;15(12):e102015. doi: 10.1136/bmjopen-2025-102015. PubMed 41469069 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2026, 17 months.

Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's 17 months is below that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 24, 2025
StartActual
Jan 27, 2025
Primary completionActual
Jun 29, 2026
CompletionEst.
Nov 5, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943612
Responsible party
Jens Jakob, MD (Head Sarcoma Surgery and Sarcoma Center Mannheim, Heidelberg University, Heidelberg University) — Principal investigator
First posted
Apr 24, 2025
Start date
Jan 27, 2025
Primary completion
Jun 29, 2026
Completion
Nov 5, 2026 (estimated)
Last update
Jul 23, 2026

Study contacts

Jens Jakob, Prof.
Contact
Jens.Jakob@umm.de
+49 621 383 2447
Madelaine Hettler, Dr.
Contact
madelainehenny.hettler@umm.de
Jens Jakob, Prof.
principal investigator · Sarcoma Unit, Department of Surgery, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion